Your browser doesn't support javascript.
loading
Fractionated vs single-dose gemtuzumab ozogamicin with determinants of benefit in older patients with AML: the UK NCRI AML18 trial.
Freeman, Sylvie D; Thomas, Abin; Thomas, Ian; Hills, Robert K; Vyas, Paresh; Gilkes, Amanda; Metzner, Marlen; Jakobsen, Niels Asger; Kennedy, Alison; Moore, Rachel; Almuina, Nuria Marquez; Burns, Sarah; King, Sophie; Andrew, Georgia; Gallagher, Kathleen M E; Sellar, Rob S; Cahalin, Paul; Weber, Duruta; Dennis, Mike; Mehta, Priyanka; Knapper, Steven; Russell, Nigel H.
Afiliación
  • Freeman SD; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United Kingdom.
  • Thomas A; Centre for Trials Research, Cardiff University, Cardiff, United Kingdom.
  • Thomas I; Centre for Trials Research, Cardiff University, Cardiff, United Kingdom.
  • Hills RK; Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom.
  • Vyas P; Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom.
  • Gilkes A; Cardiff University School of Medicine, Cardiff, United Kingdom.
  • Metzner M; Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom.
  • Jakobsen NA; Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom.
  • Kennedy A; Wellcome, Medical Research Council Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom.
  • Moore R; Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom.
  • Almuina NM; Centre for Trials Research, Cardiff University, Cardiff, United Kingdom.
  • Burns S; Centre for Trials Research, Cardiff University, Cardiff, United Kingdom.
  • King S; Centre for Trials Research, Cardiff University, Cardiff, United Kingdom.
  • Andrew G; Laboratory of Myeloid Malignancies, National Heart, Lung, and Blood Institute, Bethesda, MD.
  • Gallagher KME; Cellular Immunotherapy Program, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA.
  • Sellar RS; UCL Cancer Institute and University College London Hospital, London, United Kingdom.
  • Cahalin P; Blackpool Teaching Hospitals National Health Service Foundation Trust, Blackpool, United Kingdom.
  • Weber D; Odense University Hospital, Odense, Denmark.
  • Dennis M; The Christie National Health Service Foundation Trust, Manchester, United Kingdom.
  • Mehta P; The University of Bristol and Weston National Health Service Trust, Bristol, United Kingdom.
  • Knapper S; Cardiff University School of Medicine, Cardiff, United Kingdom.
  • Russell NH; Guy's and St Thomas' National Health Service Foundation Trust, London, United Kingdom.
Blood ; 142(20): 1697-1707, 2023 11 16.
Article en En | MEDLINE | ID: mdl-37595359
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Leucemia Mieloide Aguda / Daunorrubicina Tipo de estudio: Clinical_trials Límite: Aged / Humans País/Región como asunto: Europa Idioma: En Revista: Blood Año: 2023 Tipo del documento: Article País de afiliación: Reino Unido
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Leucemia Mieloide Aguda / Daunorrubicina Tipo de estudio: Clinical_trials Límite: Aged / Humans País/Región como asunto: Europa Idioma: En Revista: Blood Año: 2023 Tipo del documento: Article País de afiliación: Reino Unido